Thalidomide: near complete regression of extramedullary bulk in refractory multiple myeloma

Andreas Trojan1, A Anagnostara2, Lorenz Jost3

1 Division of Oncology, Department of Internal Medicine, University Hospital, Zurich, Switzerland
2 Institute for Neuroradiology, Department of Radiology, University Hospital, Zurich, Switzerland

Multiple myeloma is a malignancy with a disappointing survival rate for patients treated by conventional chemotherapy. Despite intensive chemotherapy, local irradiation and high dose chemotherapy followed by autologous transplantation, this 47-year-old patient relapsed and developed a refractory tumour bulk at the cervico-thoracic junction. Painful compression of the spinal cord (Figure 1, a, b) with paraesthesia of the arm receded a few weeks after initiation of single drug therapy with thalidomide at 100-200 mg/day. Urinary light chain excretion gradually dropped from 1.1 g/day to <0.01 g/day within a four months’ period. 1-year follow-up MRI reveals a significant regression of the medullary infiltration and the paravertebral extramedullary tumor masses (Figure 1, c, d). No neuropathy, constipation, fatigue, arrhythmia, skin rash, hypotension or neutropenia were noted. Whether angiogenic effects or e.g. modulation of autocrine cytokine loops lead to response in multiple myeloma is not entirely clear.

Figure 1
a. Sagittal T2-weighted scan: medullary infiltration of segments C6-Th1 (⇒), pathological fracture of the vertebral body of C7 and Th1, secondary gibbus formation. Myelon compression by epidural component of the myeloma mass (△). Extramedullary tumor bulk (▲).

Correspondence:
Dr. A. Trojan
Division of Oncology
Department of Internal Medicine
University Hospital
CH-8091 Zurich

References
The many reasons why you should choose SMW to publish your research

What Swiss Medical Weekly has to offer:

- SMW’s impact factor has been steadily rising, to the current 1.537
- Open access to the publication via the Internet, therefore wide audience and impact
- Rapid listing in Medline
- LinkOut-button from PubMed with link to the full text website http://www.smw.ch (direct link from each SMW record in PubMed)
- No-nonsense submission – you submit a single copy of your manuscript by e-mail attachment
- Peer review based on a broad spectrum of international academic referees
- Assistance of our professional statistician for every article with statistical analyses
- Fast peer review, by e-mail exchange with the referees
- Prompt decisions based on weekly conferences of the Editorial Board
- Prompt notification on the status of your manuscript by e-mail
- Professional English copy editing
- No page charges and attractive colour offprints at no extra cost

Editorial Board
Prof. Jean-Michel Dayer, Geneva
Prof. Peter Gehr, Berne
Prof. André P. Perruchoud, Basel
Prof. Andreas Schaffner, Zurich
(Chairman)
Prof. Werner Straub, Berne
Prof. Ludwig von Segesser, Lausanne

International Advisory Committee
Prof. K. E. Juhani Airaksinen, Turku, Finland
Prof. Anthony Bayes de Luna, Barcelona, Spain
Prof. Hubert E. Blum, Freiburg, Germany
Prof. Walter E. Haefeli, Heidelberg, Germany
Prof. Nino Kuenzli, Los Angeles, USA
Prof. René Lutter, Amsterdam, The Netherlands
Prof. Claude Martin, Marseille, France
Prof. Josef Patsch, Innsbruck, Austria
Prof. Luigi Tavazzi, Pavia, Italy

We evaluate manuscripts of broad clinical interest from all specialities, including experimental medicine and clinical investigation.

We look forward to receiving your paper!

Guidelines for authors:
http://www.smw.ch/set_authors.html

All manuscripts should be sent in electronic form, to:

EMH Swiss Medical Publishers Ltd.
SMW Editorial Secretariat
Farnburgerstrasse 8
CH-4132 Muttenz

Manuscripts: submission@smw.ch
Letters to the editor: letters@smw.ch
Editorial Board: red@smw.ch
Internet: http://www.smw.ch